Sinnow Medical: The dual anti-platelet therapy for coronary stent products has been approved by the European Union to be shortened to 1 month for all populations.

Sinomedical announced that the company recently received approval from the European Union regulatory agency to update the product label of its HTSupreme drug-eluting stent system in the EU. The update includes the statement "after implantation in the entire coronary heart disease population, dual antiplatelet therapy duration can be shortened to 1 month." This approval is based on the company's key clinical study, PIONEERIV, which was published in the European Heart Journal in February 2026. This marks a significant advancement in optimizing postoperative medication regimens for coronary heart disease intervention therapy globally, enhancing the competitiveness of the product in the European and global markets.